Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older
This study has been completed.
Study NCT00048503 Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received on November 1, 2002. Last Updated on April 23, 2010
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Myeloid Leukemia
Additional conditions recognized in this trial
Leukemia, Myeloid, Acute
More general conditions related to this trial
Neoplasms by Histologic Type
Interventions listed in this trial
ZARNESTRA, tipifarnib, R115777
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Sponsors listed in this trial
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers